Matthew Ocko - 19 Oct 2022 Form 4 Insider Report for Zymergen Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 19 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2022, 19:15:33 UTC
Prior SEC filing: 07 Sep 2021
Next SEC filing: 18 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Celeste Ferber, attorney-in-fact

Key filing fact

Matthew Ocko filed Form 4 for Zymergen Inc. on 19 Oct 2022.

Key facts

This page summarizes Matthew Ocko's Form 4 filing for Zymergen Inc..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 Oct 2022, 19:15.

Change

Previous filing in this sequence was filed on 07 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZY transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2,448,901
Change %: -100%
Price
Shares after: 0
Date: 19 Oct 2022
Ownership: See footnote
Footnotes: F1, F2

ZY transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -4,917,734
Change %: -100%
Price
Shares after: 0
Date: 19 Oct 2022
Ownership: See footnote
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Matthew Ocko is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo, together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.

Footnote F2

Represents shares held of record by Data Collective II, L.P. ("DCVC II"). Data Collective II GP, LLC ("DCVC II GP") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any.

Footnote F3

Represents shares held of record by DCVC Opportunity Fund, L.P. ("DCVC Opportunity Fund"). DCVC Opportunity Fund GP, LLC ("DCVC Opportunity Fund GP") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund. The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any.